GlassScriptPhysician profile
Neel Talwar
NPI 1477977114
$2,891.33
in general payments reported to CMS, 2019-2025
17 companies · $38.62 in 2025
The $38.62 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $337 · 2020: $213 · 2021: $910 · 2022: $375 · 2023: $623 · 2024: $395 · 2025: $38.62.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $500 · Education: $373 · Food and Beverage: $183.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $500.00 |
| Education | $373.49 |
| Food and Beverage | $182.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $500.00 | 2023 | Enhertu |
| Lilly USA, LLC | $354.59 | 2021-2024 | Verzenio |
| Aveo Pharmaceuticals, INC. | $324.68 | 2021-2024 | |
| Astrazeneca Pharmaceuticals LP | $319.94 | 2020-2021 | |
| Novocure Gmbh | $250.00 | 2022 | |
| Genentech USA, INC. | $237.70 | 2019 | |
| Iovance Biotherapeutics, INC. | $137.38 | 2024 | Amtagvi |
| Incyte Corporation | $134.55 | 2021 | |
| Karyopharm Therapeutics INC. | $129.93 | 2020-2021 | |
| E.R. Squibb & Sons, L.L.C. | $108.07 | 2021 | |
| Alexion Pharmaceuticals, INC. | $99.00 | 2019 | |
| Glaxosmithkline, LLC. | $98.99 | 2021 | |
| Coherus Oncology, INC. | $70.98 | 2021 | |
| Merck Sharp & Dohme LLC | $53.28 | 2022-2024 | Keytruda |
| Janssen Pharmaceuticals, INC | $43.40 | 2024-2025 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $16.92 | 2025 | Tecvayli, Talvey |
| Gilead Sciences, INC. | $11.92 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Neel Talwar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.